Renal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure
Open Access
- 1 May 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 3 (3) , 412-419
Abstract
Background—: Hemodynamic and neurohumoral function can affect the efficacy of diuretic therapy in congestive heart failure. Arginine vasopressin increases water reabsorption through the V 2 receptor in the collecting duct, whereas B-type natriuretic peptide (BNP) decreases sodium reabsorption in the collecting duct. We hypothesized that combining BNP to the V 2 -receptor antagonist tolvaptan (TLV) would enhance renal excretory function by augmenting sodium excretion together with aquaresis without adversely affecting renal hemodynamics in experimental congestive heart failure. Methods and Results—: Congestive heart failure was induced in 3 groups (n=6 per group) of dogs by tachypacing. A acute experiment was done after 10 days. After baseline measurements, study groups received a 0.1 mg/kg IV bolus of TLV alone (TLV), TLV in combination with BNP (TLV+BNP; 50 ng/[kg · min]), or BNP alone (BNP). Mean arterial pressure increased with TLV, remained unchanged with TLV+BNP, and decreased with BNP (+5±1mm Hg versus −1±1 mm Hg versus −15±1 mm Hg; P P P P P <0.05). Conclusions—: Coadministration of TLV and BNP in experimental HF resulted in a beneficial profile of renal, neurohumoral, and hemodynamic actions, specifically potent diuresis with natriuresis, neutral effect on mean arterial pressure, and lack of aldosterone activation.Keywords
This publication has 33 references indexed in Scilit:
- Atrial natriuretic peptide and nitric oxide signaling antagonizes vasopressin-mediated water permeability in inner medullary collecting duct cellsAmerican Journal of Physiology-Renal Physiology, 2009
- Detection of Endogenous B-Type Natriuretic Peptide at Very Low Concentrations in Patients With Heart FailureCirculation: Heart Failure, 2008
- Acute Hemodynamic Effects of Tolvaptan, a Vasopressin V2 Receptor Blocker, in Patients With Symptomatic Heart Failure and Systolic DysfunctionJACC, 2008
- Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cellsAmerican Journal of Physiology-Renal Physiology, 2008
- Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registryEuropean Heart Journal, 2007
- Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart FailureCirculation, 2006
- Nesiritide Does Not Improve Renal Function in Patients With Chronic Heart Failure and Worsening Serum CreatinineCirculation, 2004
- Natriuretic peptides in the treatment of heart failureJournal of Cardiac Failure, 1996
- Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics.Heart, 1987
- Increased plasma arginine vasopressin levels in patients with congestive heart failureJACC, 1983